Eupraxia Pharmaceuticals Inc. reported second-quarter earnings per share (EPS) of $(0.23), beating the analyst consensus estimate of $(0.25) by 8 percent. The clinical-stage biotechnology company leveraged its proprietary Diffusphere™ technology to advance its lead asset EP-104GI for Eosinophilic Esophagitis (EoE), while recording a wider net loss of $14.5 million for the three months ended June 30, 2026, compared to $8.7 million in the same period last year.

The beat in per-share metrics occurred alongside an 11.54 percent increase in losses from $(0.26) per share in Q2 2025, driven primarily by increased investment in clinical programs. Management attributed the higher costs to doubling the size of the RESOLVE Part 2 trial and increased general and administrative expenses, partially offset by a rise in other income.

Financial Performance and Balance Sheet

The company’s financial position remains stable with sufficient liquidity to fund operations into the second half of 2028. As of June 30, 2026, Eupraxia held cash and cash equivalents of $52.4 million and short-term investments of $81.2 million. This represents a decrease from the aggregate cash balance of $80.6 million reported at the end of the fourth quarter of 2025.

On a capital structure basis, the company had 65,474,223 common shares outstanding, 8,295,638 preferred shares outstanding, and 1,428,571 pre-funded warrants as of June 30, 2026.

Clinical Milestones and Operational Updates

The quarter featured significant progress in the RESOLVE trial for EoE. Data released on April 21, 2026, showed that patients in Cohort 9 (n=3) achieved the highest response in tissue health at week 36 compared to all other dose cohorts. Clinical remission in symptoms was maintained in 66% of these patients at week 36, a level first achieved at week 8 and sustained through the nine-month period.

At Digestive Disease Week (DDW) in May, Eupraxia presented EREFS data demonstrating a relationship between the number of EP-104GI injections and improvements in inflammation and fibrosis severity. Additionally, EoEHSS sub-score data from the highest dose cohorts were reported for the first time, generally showing improvement in both inflammation and fibrosis following treatment.

Leadership Changes

Eupraxia strengthened its executive team and board during the quarter to support late-stage development. Dr. Jeff Millard was added as Executive Vice President, Technical Operations, and Dr. Alex Therien was named Executive Vice President, Research & Development, on July 13, 2026. Dr. Jeymi Tambiah was appointed Chief Medical Officer on May 4, 2026.

The company also announced the transition of its operations from Victoria to a two-hub organization based in Vancouver and Seattle. Consequently, Amanda Malone stepped down from her role as Chief Scientific and Operating Officer. New board members Robert Bazemore, Amy Pott, and Dr. Helen Thackray were appointed on July 7, 2026.

What the Numbers Show

The divergence between the widened net loss and the positive EPS surprise highlights the impact of capital structure dynamics on per-share metrics. While operational expenditures rose significantly due to the expansion of the RESOLVE Part 2 trial, the EPS beat suggests that dilution effects or other income components mitigated the per-share impact of the higher absolute losses. This underscores the importance of monitoring not just aggregate profitability but also share count adjustments and non-operating income streams in clinical-stage biotechs.

Eupraxia Pharmaceuticals Inc. has strengthened its executive leadership team to support its next phase of clinical and commercial development. The clinical-stage biotechnology company appointed Dr. Jeff Millard as Executive Vice President, Technical Operations, and Dr. Alex Therien as Executive Vice President, Research & Development, effective July 13, 2026. These changes come as Eupraxia prepares for the Q4 2026 interim release of its RESOLVE trial in Eosinophilic Esophagitis (EOE) and transitions to a cross-border two-hub organization.

Dr. Millard brings nearly 25 years of leadership experience in technical operations, CMC, and regulatory strategy. He previously held senior leadership positions at Ensysce Biosciences, Microbion Corporation, and Cascadian Therapeutics. At Eupraxia, he will lead critical functions focused on the transition from development to commercialization, with a specific emphasis on the success of EP104GI.

Dr. Therien, who joined Eupraxia in November 2025, assumes leadership of Research & Development. He brings more than 20 years of biopharmaceutical leadership experience, having held senior roles at Generate Biomedicines, Eikon Therapeutics, and Merck. His appointment is aimed at driving portfolio expansion at the company.

As part of the organizational evolution, Eupraxia has completed the transition of its operations from Victoria to Vancouver and Seattle. This shift reflects the company's focus on supporting growing clinical operations. Key clinical, manufacturing, and commercial executive leadership positions, including the CEO, will be based in the Seattle offices.

Amanda Malone has stepped down from her role as Chief Scientific and Operating Officer, effective July 10, 2026. The company acknowledged her contributions in research and early-stage development during her tenure based in Victoria.

Executive Appointments

Eupraxia's proprietary Diffusphere technology is designed to optimize local, controlled drug delivery. The company's lead product candidate, EP-104GI, is currently in a Phase 1b/2 trial for the treatment of EoE. Additionally, Eupraxia completed a Phase 2b clinical trial of EP-104IAR for pain due to knee osteoarthritis, which met its primary endpoint and three of four secondary endpoints.